Host |
Monospecific Mouse |
Klon |
ZM95 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
Lokalisation |
Nucleus |
NKX3-1
|
Zeta Corporation |
ZM95 |
0.5 ml |
Concentrate |
CE/IVD |
Z2395MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM95 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
Lokalisation |
Nucleus |
NKX3-1
|
Zeta Corporation |
ZM95 |
0.1 ml |
Concentrate |
CE/IVD |
Z2395MT |
-
|
Host |
Rabbit |
Klon |
D2Y1A |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Prostate cancer |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
7 ml |
Ready-to-use |
CE/IVD |
ALI3260G7 |
-
|
Host |
Rabbit |
Klon |
D2Y1A |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Prostate cancer |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
6 ml |
Ready-to-use |
CE/IVD |
AVI3260G |
-
|
Host |
Mouse |
Klon |
361 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
1 ml |
Concentrate |
CE/IVD |
MOB569 |
-
|
Host |
Mouse |
Klon |
361 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
0.1 ml |
Concentrate |
CE/IVD |
MOB569-01 |
-
|
Host |
Mouse |
Klon |
361 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
0.5 ml |
Concentrate |
CE/IVD |
MOB569-05 |
-
|
Host |
Mouse |
Klon |
361 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
6 ml |
Ready-to-use |
CE/IVD |
PDM569 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to aa 569-588 of human Nrf2 protein. |
Lokalisation |
Nuclear, Cytoplasmic |
Nrf2 (TCF11)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
514-12504 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, CH, DG, MS, RB, RT |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:300 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminal of human NSE. |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
514-3302 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, CH, DG, MS, RB, RT |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:300 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminal of human NSE. |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
514-3304 |
-
|
Host |
Mouse |
Klon |
DBMM4.507 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b/kappa |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
1 ml |
Concentrate |
CE/IVD |
MOB616 |
-
|
Host |
Mouse |
Klon |
DBMM4.507 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b/kappa |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
0.1 ml |
Concentrate |
CE/IVD |
MOB616-01 |
-
|
Host |
Mouse |
Klon |
DBMM4.507 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b/kappa |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
0.5 ml |
Concentrate |
CE/IVD |
MOB616-05 |
-
|
Host |
Mouse |
Klon |
DBMM4.507 |
Format |
ready-to-use |
Methode |
P |
Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
Verdünnung |
--- |
Isotyp |
IgG2b/kappa |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
6 ml |
ready-to-use |
CE/IVD |
PDM616 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR006 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP054 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP054-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP054-05 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM24 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
1 ml |
Concentrate |
CE/IVD |
Z2351ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM24 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or brain. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
7 ml |
Ready-to-use |
CE/IVD |
Z2351MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM24 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
0.5 ml |
Concentrate |
CE/IVD |
Z2351MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM24 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
0.1 ml |
Concentrate |
CE/IVD |
Z2351MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM82 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human NPM1 protein fragment (aa185-287) |
Lokalisation |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
1 ml |
Concentrate |
CE/IVD |
Z2405ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM82 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human NPM1 protein fragment (aa185-287) |
Lokalisation |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
7 ml |
Ready-to-use |
CE/IVD |
Z2405MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM82 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human NPM1 protein fragment (aa185-287) |
Lokalisation |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
0.5 ml |
Concentrate |
CE/IVD |
Z2405MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM82 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human NPM1 protein fragment (aa185-287) |
Lokalisation |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
0.1 ml |
Concentrate |
CE/IVD |
Z2405MT |
-
|
|
Nuclear Protein in Testis |
Host |
Rabbit |
Klon |
ZR456 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
NUT carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
A peptide corresponding to human NUT proteinund aa1-100) of human Claudin18.2 protein |
Lokalisation |
Nucleus |
NUT
|
Zeta Corporation |
ZR456 |
1 ml |
Concentrate |
RUO |
Z2810RL-R |
-
|
Host |
Rabbit |
Klon |
DBRRM7.36 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Testis |
Verdünnung |
1:50-1:100 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB115R |
-
|
Host |
Rabbit |
Klon |
DBRRM7.36 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Testis |
Verdünnung |
1:50-1:100 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB115R-01 |
-
|
Host |
Rabbit |
Klon |
DBRRM7.36 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Testis |
Verdünnung |
1:50-1:100 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB115R-05 |
-
|
Host |
Rabbit |
Klon |
DBRRM7.36 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Testis |
Verdünnung |
--- |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD115R |
-
|
Host |
Rabbit |
Klon |
ZR227 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
B-cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
Lokalisation |
Nuclear |
OCT-2
|
Zeta Corporation |
ZR227 |
0.1 ml |
Concentrate |
CE/IVD |
Z2708RT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM90 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
1 ml |
Concentrate |
CE/IVD |
Z2400ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM90 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
B-cell lymphoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
7 ml |
Ready-to-use |
CE/IVD |
Z2400MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM90 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
0.5 ml |
Concentrate |
CE/IVD |
Z2400MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM90 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
0.1 ml |
Concentrate |
CE/IVD |
Z2400MT |
-
|
Host |
Mouse |
Klon |
OCT4/6847R |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate Buffer pH 6.0 |
Positivkontrolle |
Seminoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b |
Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
1 ml |
Concentrate |
CE/IVD |
RMAB113 |
-
|
Host |
Mouse |
Klon |
OCT4/6847R |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate Buffer pH 6.0 |
Positivkontrolle |
Seminoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b |
Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
0.1 ml |
Concentrate |
CE/IVD |
RMAB113-01 |
-
|
Host |
Mouse |
Klon |
OCT4/6847R |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate Buffer pH 6.0 |
Positivkontrolle |
Seminoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b |
Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
0.5 ml |
Concentrate |
CE/IVD |
RMAB113-05 |
-
|
Host |
Mouse |
Klon |
OCT4/6847R |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate Buffer pH 6.0 |
Positivkontrolle |
Seminoma |
Verdünnung |
--- |
Isotyp |
Mouse IgG2b |
Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
6 ml |
ready-to-use |
CE/IVD |
RMPD113 |
-
|
Host |
Rabbit |
Klon |
ZR364 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
Lokalisation |
Nuclea |
OCT-4
|
Zeta Corporation |
ZR364 |
1ml |
Concentrate |
CE/IVD |
Z2604RL |
-
|
Host |
Rabbit |
Klon |
ZR364 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
Lokalisation |
Nuclear |
OCT-4
|
Zeta Corporation |
ZR364 |
7 ml |
ready-to-use |
CE/IVD |
Z2604RP |
-
|
Host |
Rabbit |
Klon |
ZR364 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
Lokalisation |
Nuclea |
OCT-4
|
Zeta Corporation |
ZR364 |
0.5 ml |
Concentrate |
CE/IVD |
Z2604RS |
-
|
Host |
Rabbit |
Klon |
ZR364 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
Lokalisation |
Nuclea |
OCT-4
|
Zeta Corporation |
ZR364 |
0.1 ml |
Concentrate |
CE/IVD |
Z2604RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Seminom |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK017-05 |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Seminoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b /κ |
Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2104ML |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Seminoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2104MP |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Seminoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b /κ |
Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2104MS |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Seminoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b /κ |
Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2104MT |
-
|